Abstract--We studied the occurrence of T-cell subpopulations for patients with B-cell chronic lymphocytic leukemia. The CD8 ÷ population was divided into CD8 ÷ suppressor (CD8a ÷) and CD8 ÷ cytotoxic (CD8b ÷) lymphocytes using difference in orthogonal light scattering.
INTRODUCTION
VARIOUS T-cell abnormalities have been reported for B-chronic lymphocytic leukemia (B-CLL) patients. Most authors describe an increase in CD8 positive lymphocytes (CD8 ÷) and a decrease in CD4 positive lymphocytes (CD4 ÷) [1] [2] [3] [4] [5] [6] [7] [8] . Functional T-cell studies yield contradictory results; normal [9] or decreased helper function is described [10] [11] [12] as well as decreased [13] or increased suppressor function [14, 15] .
We have shown previously that using flow cytometry (FCM) two populations of lymphocytes can be distinguished by measuring the light scattering signal in the orthogonal direction [16] . It was demonstrated that these subpopulations consist of regulatory and Blymphocytes (low orthogonal light scattering signal) and cytotoxic lymphocytes (high orthogonal light scattering signal). In another report we have shown that the CD8 + lymphocyte population could be divided in a suppressor-and a cytotoxic lymphocyte CD8 + subpopulation [17] .
In this study we have used FCM to get more detailed insight in the occurrence of CD8 + suppressor and CD8 ÷ cytotoxic lymphocytes in peripheral blood of B-CLL patients.
MATERIALS AND METHODS

Patient populations
The study included 22 patients with B-CLL with a mean age of 59 (range 41-85). The patients were graded using the Rai clinical staging [18] . Seven patients with stage 0 with no progression for at least two years were included, one of them was previously treated because of severe disease (IV Rai). Four patients graded stage 0 in partial remission, all previously stage IV and successfully treated with chlorambucil sometimes in combination with prednisolone. These patients received maintenance treatment. Also included were four patients graded stage IV, two patients with stage III and one patient with stage II before receiving any treatment and four patients graded stage IV showing not or insufficient § improvement after treatment of at least one year with chlorambucil sometimes in combination with prednisolone.
Preparation of lymphocytes
Human blood was collected between 8 and 9 p.m. by venipuncture into vacutainer tubes containing heparin as anticoagulant (150 USP U sodium heparine/10 ml VenoAbbreviations: B-CLL, B-cell chronic lymphocytic leukemia; FCM, flow cytometer; FITC-GAM, fluorescein isothiocyanate labeled goat antimouse immunoglobulin.
Correspondence to: Dr J. Greve, University of Twente, Dept of Applied Physics, Cell Characterization Group, P.O. Box 217, 7500 AE Enschede, The Netherlands. ~No improvement is defined as no improvement of white blood and thrombocyte count as well as hemoglobin concentration.
§Insufficient improvement is defined as a decrease in white blood cell count but no improvement of thrombocyte count and hemoglobin concentration, ject Terumo Europe NV). Lymphocytes were obtained after density separation as described in detail elsewhere [17] . Lymphocytes were adjusted to a concentration of 1.107 lymphocytes per ml with a standard buffer (PBS containing 0.05% sodium azide and 1% bovine serum albumin (BSA)).
lmmunofluorescence
The following monoclonal antibodies (Mabs) were used: (a) unlabelled Mabs: CD8 (anti-leu2a, from Becton Dickinson, Amersfoort, The Netherlands) T suppressor-cytotoxic marker; CD4 (RIV 6, from National Institute for Public Health and Milieu (RIVM), Rijswijk, The Netherlands) T helper-inducer marker; CD3 (RIV 3, from RIVM) pan T-cell marker; (b)fluorescein (FITC) labeled Mabs: CD3 (anti-leu4, from Becton Dickinson), CD4 (anti-leu3a, from Becton Dickinson); (c)phycoerythrine (PE) labeled Mab: CD8 (anti-leu2a, from Becton Dickinson). For second step reagents FITC conjugated goat antimouse immunoglobulin (FITC GAM) (Central Laboratory of Blood Transfusion Service (CLB) Amsterdam, The Netherlands) was used. All reagents were pretitered by using normal lymphocytes to determine optimal conditions for binding. One hundred microliters of cell suspension was incubated with 20 fxl diluted Mab. Mabs were diluted in standard buffer for 30 min at room temperature. For indirect fluorescence the cells were washed twice with standard buffer and resuspended in 100 p,l diluted second step reagent. The cells were incubated for 30 min at room temperature. After incubation the cells were washed twice and resuspended in 1-ml standard buffer and kept on ice until use.
Flow cytometric analysis was performed the same day to preserve both optimal binding of monoclonal antibody and light scatter properties of lymphocytes [19, 20] .
Flow cytometry measurements
The FCM was described in detail elsewhere [17] . A 3-W argon ion laser tuned at 488 nm operating at a light intensity of 100mW was used. 
RESULTS
Methodology
Choice of stain. The relative number of T lymphocytes in B-CLL patients can be reduced from 60 to 80% of the total number of lymphocytes to 2% or less. In order to obtain reliable data on relative and absolute occurrence of the T-cell subsets amongst all lymphocytes one therefore has to study a large number of cells in a very selective way.
With the monoclonal antibodies used CD3, CD4 and CD8 the selectivity condition is met. In flow cytometry the presence of monoclonal antibodies on cell surfaces is detected with either direct or indirect immunofluorescence staining. We have compared direct and indirect immunofluorescence staining in order to investigate the possibility of detecting positive cells that occur in a frequency below 1%.
When using the direct immunofluorescence labeling, no reliable data can be obtained when positive cells occur in a frequency of 2% or less, since 1.3% of GAM stained lymphocytes are false positive. With direct immunofluorescence labeling using a fluorescently labeled irrelevant antibody (Igl-FITC) as control, down to 0-05% positive cells can be detected in a reliable way. All further data given in this paper were therefore obtained by using direct immunofluorescence labeling.
CD8a and CD8b determination
Determination of CD8 + subpopulations was performed by dividing the orthogonal light scatter histograms into two components with a low (CD8a) and a large (CD8b) orthogonal light scattering signal as described in detail in earlier reports [16, 17] . In B-CLL patients the occurrence of both populations strongly differs from that of healthy donors as is shown in Fig. 1 for four patients and four controls. Dashed lines are indicated at the positions of the maxima of the two populations. In healthy controls two populations can be seen. In B-CLL patients the same populations are present, however, the population showing a low orthogonal light scattering intensity is very small.
Therefore it may even be that for some B-CLL patients only the population with the large orthogonal light scattering appears in the histograms. A large variation in the occurrence of CD8 + subpopulations of healthy donors is observed [17] . CD8b+/CD8 + ratios varied from 17 to 69 (mean 39). For individuals the variation in CD8b+/CD8 + ratios determined in a time period of 3 months is considerably less. We found a range of CD8b+/CD8 + ratios for one healthy donor of 24-40 (mean 36, n = 5), for one B-CLL patient graded stage 0, a range of 74-79 (mean 76, n = 3) was found and for one B-CLL patient graded stage IV a range of 91-99 (mean 95, n = 5) was found. No relation between CD8b+/ CD8 + ratio and age could be detected in the control group and the B-CLL patients.
B-CLL patients
Absolute number of T-cell subpopulations. 
Ratios of T-cell subpopulations. CD4+/CD8 +
ratio's were calculated as well as the CD4+/CD8a ÷ ratios. They are presented in Fig. 3 together with the 
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ratio of CD8 + cytotoxic lymphocytes to all CD8 + lymphocytes (CD8b+/CD8+). Patients were subdivided in early and late disease as well as treated and untreated. The B-CLL group showed decreased mean CD4+/CD8 + values (1.7-S.D. 1.0) compared with healthy donors (2.5 -+ S.D. 0.6) but a considerable number of individual CD4+/CD8 ÷ ratios fall within the normal range. When subdivided into clinical stages, stage IV patients on therapy all fall within the normal range whereas all treated stage 0 patients showed a significantly decreased CD4+/CD8 + ratio (Fig. 3a) . When the CD4+/CD8a + ratios are determined a completely new perspective is gained (Fig. 3b) . CD4+/CD8a + ratios are strongly increased in the B-CLL group also when considered individually. Exceptions are the untreated stage 0 patients where two out of seven patients showed values overlapping with the normal individuals. Note the logarithmical scale. In Fig. 3c CD8b+/CD8 + ratios are given. All patients showed an increase in CD8b+/CD8 + compared with the control group. It is remarkable that untreated stage 0 CLL patients showed a smaller increase than the other patients.
DISCUSSION
The low frequency of T lymphocytes in B-CLL patients makes it very difficult to determine relative and absolute numbers of T-cell subpopulations. In this study we demonstrate that using a flow cytometer, lymphocytes directly immunofluorescently labeled with monoclonal antibodies can be detected reliably even if they occur in a frequency down to 0.05%.
Most studies on T-cell subpopulations in B-CLL patients use T-cell enrichment by E-rosette formation and subsequent density separation for determination of T-cell subpopulations in B-CLL patients. Using this technique no accurate information on T-cell subpopulations is obtained because of variation in affinity during E-rosette formation, limited purity or enriched T cell and selective loss of T-cell subpopulations by enrichment [21] . Further complications arise from E-rosette formation by immunoglobulin positive cells [22] and presence of E receptors in B-CLL cells [23] . To our knowledge only three studies have been reported in which direct assessment of T-cell subpopulations in B-CLL is per-formed [2, 5, 8] . In these studies the median of the absolute number of T cells was enlarged especially of CD8 ÷ cells. Our results are in agreement with these studies (Fig. 2) . However, a very large patient to patient variation is observed in absolute number of CD3 ÷, CD4 ÷ and CD8 ÷ lymphocytes. Absolute number of T cells can be increased up to 17 x 106/ ml.
This could suggest monoclonal proliferation of T cells alongside the proliferating B cells. This is not the case however, because different T cell subsets, i.e. CD4 ÷, CD8 ÷, account for the increase.
Concomitant with other reported studies [1] [2] [3] [4] [5] [6] the mean CD4+/CD8 ÷ ratios in B-CLL patients is decreased (Fig. 3) . However, it is not possible to draw conclusions from an individual CD4÷/CD8 ÷ ratio measured for a patient, since substantial overlap exists between CD4÷/CD8 ÷ ratios of controls and patients. No obvious relation with advancing disease as is reported by some authors [1, 3] could be found, except for patients showing no or insufficient improvement on treatment which all showed normal CD4÷/CD8 ÷ ratios.
The CD4÷/CD8 ÷ ratio is often presented as helper/suppressor ratio. However, using this definition heterogeneity of CD8 ÷ lymphocytes is not taken in consideration. In this study we have shown that with B-CLL patients this leads to completely wrong conclusions as becomes clear when CD4÷/ CD8a ratios are determined. This ratio more closely represents the helper/suppressor ratios [17] . The ratios are all strongly increased which suggest a relative increase of helper lymphocytes instead of the assumed increase of suppressor lymphocytes. Only two patients with benign disease showed a normal CD4/CD8a ratio whereas for the other five patients the relative increase was less as compared with the other groups (Fig. 3b) .
With the determination of the CD4÷/CD8b ÷ ratios a clear new view on T-cell subsets in B-CLL is revealed. No increase of suppressor lymphocytes is evoked by the proliferating B lymphocytes as is suggested by others [3] , but an increase of CD8 ÷ cytotoxic lymphocytes. This is clearly demonstrated by the determination of the contribution of CD8 ÷ cytotoxic lymphocytes to the CD8 ÷ population (CD8b÷/ CD8 ÷) which is strongly increased in all B-CLL patients (Fig. 3c) . Since the absolute number of CD8 ÷ lymphocytes was not decreased in B-CLL patients (Fig. 2c) , the increase of CD8b÷/CD8 ÷ is due to an increase of the absolute number of CD8b ÷ lymphocytes. An obvious relation with advancement of disease is found: all untreated stage 0 patients showed significantly less increased CD8b÷/CD8 + ratio than patients on therapy and patients with advancing disease. The CD8b÷/CD8 ÷ may be a parameter which can give an indication on prognosis or the results of treatment. (This is suggested by the well-known fact that prognosis of treated patients in partial remission is worse as compared with untreated stage 0 patients.) In agreement with this, one patient initially treated but in remission for three years had also a less increased CD8b÷/CD8 ÷ ratio (patient 7, Table 1 ). The suggestion that increase in CD8 ÷ or Ty ÷ lymphocytes in B-CLL patients [1] is doubtful, since we have shown that this increase is merely due to increase of CD8 ÷ cytotoxic lymphocytes. An attractive alternative hypothesis is that the hypogamma globulinaemia is due to a decrease of normal B lymphocytes.
Support for an important influence of cytotoxic lymphocytes in B-CLL patients is given by studies where a significant increase of HNK-1 (leu7) lymphocytes is found in B-CLL [8, 24] . Studies on helper and suppressor function in B-CLL patients give contradicting results. Increased [14, 15] or decreased [13] suppressor as well as increased [10] [11] [12] or normal [9] helper function are described. These contradictions could be caused by different methodology. It has to be noted that we have demonstrated that the CD8b ÷ lymphocytes in B-CLL patients have the physical properties and membrane receptor characteristics of cytotoxic lymphocytes. Our results suggest that functional studies of cytotoxic lymphocytes in B-CLL patients may be of great importance. The functional properties of these lymphocytes are still under investigation. An interesting hypothesis is that the number of cytotoxic lymphocytes is increased in B-CLL patients because the immune system is involved in an active battle against the leukemic cells. If it is assumed that these cytotoxic cells are made because they are directed specifically against leukemic cells, the decreased cytotoxicity found in NK cell assays and antibody dependent cytotoxicity mediated assays in B-CLL patients is explained since in these assays the cytotoxicity for other cell types is tested [24] [25] [26] . If these hypothesis are true new prospectives for the understanding and treatment of leukemic diseases are revealed.
